Predictive Oncology Corp (POAI) - Cumulative Company Assets

Public company logo of Predictive Oncology (POAI)

Predictive Oncology develops AI solutions for pharmaceutical corporations, leveraging its own biobank to accelerate the discovery of anti-tumor agents. The price trend of total assets, which currently stands at 5.35, links the technology stack with a team of leading oncologists attracted by academic freedom. However, a chronic lack of profitability due to the slow adoption of software within the industry creates certain financial risks.

Predictive Oncology (POAI) Company Total Assets: for the period 07/04/2022 - 12/12/2025

Comprehensive metric breakdowns and analytics for predictive-oncology.com (POAI)

- price and consensus price forecast:
Market Chart Predictive Oncology Inc.|POAI - Price Target Chart
- market capitalization data:
Market Valuation POAI|POAI - Enterprise Value
- book capitalization data:
Net Asset Value per Share Predictive Oncology|POAI - Book Capitalization|Capitalization to Book Value Ratio predictive-oncology.com|POAI - Company Total Assets
- debt and liquidity data:
Total Debt to Capital Coefficient Predictive Oncology|POAI - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio Predictive Oncology Inc.|POAI - Company Aggregate Debts|Debts to Book Capitalization POAI
Fundamental valuation:Predictive Oncology Corp, POAI
Manufactured product of Predictive Oncology Inc

This indicator reflects the aggregate volume of business resources and liabilities, calculated inversely via return on assets (ROA) to identify hidden risks of balance sheet inflation. The trend in consolidated assets demonstrates how effectively Predictive Oncology (POAI) capitalizes on its precision medicine AI ecosystem and tumor cell databases to scale its oncology intelligence center.

Main competitors

ISRG (intuitive.com) - Company Total Asset Base|Aggregate Company Assets DHR|Cumulative Company Assets BD|STERIS Corporation - Company Total Assets|Company Assets West Pharma Corp (WST)|BAX - Company Total Assets|Total Business Assets masimo.com MASI|Company Total Assets STVN (Stevanato Group)|TFX - Company Total Asset Base|MMSI (Merit Medical Systems Inc) - Company Total Assets|Nobel Biocare (NVST) - Cumulative Company Assets|ICUI (ICU Medical, Inc.) - Company Total Assets|Company Total Assets XRAY|Aggregate Company Assets LeMaitre Vascular (LMAT)|Aggregate Company Assets AtriCure Inc ATRC|Cumulative Company Assets STAAR Surgical Corp|Aggregate Asset Value ChromaDex NAGE|Company Total Assets ZIMV (ZimVie Inc.)|ANGO: Company Total Asset Base|Aggregate Company Assets Cerus|TKNO (Alpha Teknova) - Total Business Assets|MGRM: Aggregate Company Assets|Company Total Asset Base Sharps Tech (STSS)|Cumulative Company Assets InfuSystem Holdings|Aggregate Business Assets UTMD (utahmed.com)|Aggregate Company Assets KORU Medical|NYXH - Aggregate Asset Value|Microbot Medical Inc - Cumulative Company Assets|PDEX: Company Total Assets|ZTEK (Zentek Ltd.) - Aggregate Company Assets|elutia.com (ELUT) - Cumulative Company Assets|Company Total Assets MLSS (Milestone Scientific Inc.)|Company Assets NXGL|Aggregate Company Assets Retractable Technologies RVP|Total Business Assets harvardbioscience.com HBIO|Cumulative Company Assets Femasys Inc. (FEMY)|Meihua Medical Technologies - Aggregate Business Assets|Aggregate Company Assets CJMB (Callan JMB Corp)|ATRI: Company Total Asset Base|Aggregate Company Assets NeuroMetrix Corp (NURO)